Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patients.
Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patients.
复制标题
DOI：
10.3389/fonc.2022.1033993
复制
发表时间：
2022
影响因子：
4.7
通讯作者：
中科院分区：
文献类型：
--
作者：
临床路径是循证工具，已被整合到儿科医院医学的许多方面，并已被证明有效地减少各种疾病的院内并发症。在儿科肿瘤学中，针对特定的高风险患者人群采用类似工具的速度较慢，部分原因是患者的复杂性和管理策略的变化。关于儿科肿瘤患者临床路径的已发表研究很少。新诊断为白血病或淋巴瘤的儿科患者通常会出现一种或多种“肿瘤急症”，需要紧急干预和精心的多学科护理，以防止严重后果。在这里，我们提出了两个临床路径，最近已经开发出使用多学科的方法在一个单一的机构，旨在为病人谁目前与白细胞增多症或前纵隔肿块的护理。这些临床护理路径为这些经常进入儿科重症监护室进行初始管理的患者的即时护理提供了关键框架。这些途径的目标是促进多学科合作，加快诊断，并及时简化治疗启动。对高危儿科肿瘤患者的标准化护理将最终降低与这些疾病相关的发病率和死亡率，以增加获得良好结局的可能性。
Clinical pathways are evidence-based tools that have been integrated into many aspects of pediatric hospital medicine and have proven effective at reducing in-hospital complications from a variety of diseases. Adaptation of similar tools for specific, high-risk patient populations in pediatric oncology has been slower, in part due to patient complexities and variations in management strategies. There are few published studies of clinical pathways for pediatric oncology patients. Pediatric patients with a new diagnosis of leukemia or lymphoma often present with one or more “oncologic emergencies” that require urgent intervention and deliberate multidisciplinary care to prevent significant consequences. Here, we present two clinical pathways that have recently been developed using a multidisciplinary approach at a single institution, intended for the care of patients who present with hyperleukocytosis or an anterior mediastinal mass. These clinical care pathways have provided a critical framework for the immediate care of these patients who are often admitted to the pediatric intensive care unit for initial management. The goal of the pathways is to facilitate multidisciplinary collaborations, expedite diagnosis, and streamline timely treatment initiation. Standardizing the care of high-risk pediatric oncology patients will ultimately decrease morbidity and mortality associated with these diseases to increase the potential for excellent outcomes.
登录
查看更多内容
影响因子：
2
作者：
Rinaldi I;Sari RM;Tedhy VU;Winston K
通讯作者：
Winston K
影响因子：
2.4
作者：
Acker, Shannon N.;Linton, Jacqueline;Partrick, David A.
通讯作者：
Partrick, David A.
影响因子：
3.2
作者：
Lowe, EJ;Pui, CH;Sandlund, JT
通讯作者：
Sandlund, JT
影响因子：
1.7
作者：
Hammer, GB
通讯作者：
Hammer, GB
影响因子：
2.4
作者：
Perger, Lena;Lee, Edward Y.;Shamberger, Robert C.
通讯作者：
Shamberger, Robert C.